# Seagen Inc. – Consensus ‘hold’ rating and 8.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/seagen-inc.consensus-hold-rating-and-8.5-upside-potential-2/4121127807
- Published: 2023-09-20T13:53:06+01:00
- Author: Charlotte Edwards

**Seagen Inc.** with ticker code (SGEN) have now 12 confirmed analysts covering 
the stock with the consensus suggesting a rating of ‘hold’. The target price High/
Low ranges between 229 and 180 calculating the average target price we see $224.83.
Given that the stocks previous close was at $207.17 this now indicates there is 
a potential upside of 8.5%. There is a 50 day moving average of $198.50 and the 
200 day moving average is $179.07. The market cap for the company is 39.10B. The
current share price for the company is: 208.31 USD

 The potential market cap would be $42,432,358,444 based on the market consensus.

The company has a dividend yield of 5.95%. Other points of data to note are a P/
E ratio of -, revenue per share of 11.6 and a -12.56% return on assets.

Seagen Inc. is a biotechnology company that develops and commercializes targeted
therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or
brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV,
or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers;
TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth
factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or
tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers.
It is also advancing a pipeline of novel therapies for solid tumors and blood-related
cancers designed to address unmet medical needs and improve treatment outcomes for
patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s
antibody-drug conjugate (ADC) technology that utilizes the targeting ability of 
monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

Share on: